Applied Clinical Trials recently spoke with Oren Cohen, MD, Chief Medical and Scientific Officer for Quintiles Transnational about the CRO’s relationship with Academic Medical Centers. This interview was conducted as part of a larger article in development for our February Special Report: AMCs and Clinical Trials.
According to Cohen, Quintiles has increased its partnerships with AMCs, as well as independent medical centers, in just the past two years. “We have to wait some time before we can judge how successful these relationships are,” said Cohen. “There is the natural of life cycle of studies, which could be up to eight years to see how it goes.”
However, for Quintiles, Cohen believes these partnerships are going well. By concentrating the portfolio of studies “under one roof,” Quintiles has the following benefits:
-Faster study start-up time
-More predictable enrollment
-Access to thought-leaders
-High-concentration of efficiencies (i.e., with monitoring)
“Partnerships that make sense for efficiency are good for everybody,” said Cohen. “Times change and everybody is under more economic pressure, AMCs, CROs…airlines and the auto industry.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Oveporexton Shows Superior Efficacy in Phase II Narcolepsy Type 1 Trial Without Hepatotoxicity
May 16th 2025In the TAK-861-2001 Phase IIb study, oveporexton significantly improved wakefulness, daytime sleepiness, and cataplexy frequency in patients with narcolepsy type 1, outperforming current therapies and avoiding liver toxicity seen with earlier OX2R agonists, according to results published in The New England Journal of Medicine.